MARKET

CRVS

CRVS

Corvus Pharmaceu
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.045
-0.025
-2.34%
Closed 16:00 05/20 EDT
OPEN
1.080
PREV CLOSE
1.070
HIGH
1.090
LOW
1.000
VOLUME
338.29K
TURNOVER
199.12K
52 WEEK HIGH
9.54
52 WEEK LOW
1.000
MARKET CAP
48.65M
P/E (TTM)
-1.1645
1D
5D
1M
3M
1Y
5Y
BRIEF-Corvus Pharmaceuticals Provides Program Updates At Research And Development Symposium
reuters.com · 05/10 11:33
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium
Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical and clinical data for its three programs – mupadolimab (anti-CD73), ciforadenant (adenosine 2A receptor an...
GlobeNewswire · 05/10 11:30
Catalyst watch: Rivian lockup expires, Western Digital event and inflation prints
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 05/06 19:00
BRIEF-Corvus Pharmaceuticals Reports First Quarter 2022 Financial Results
reuters.com · 05/05 23:02
Corvus Pharmaceuticals GAAP EPS of -$0.18
Corvus Pharmaceuticals press release (NASDAQ:CRVS): Q1 GAAP EPS of -$0.18. As of March 31, 2022, Corvus had cash, cash equivalents and marketable securities totaling $62.9 million
Seekingalpha · 05/05 21:34
Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York
Company to host a webcast at 9:00am ET / 6:00am PTBURLINGAME, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an R...
GlobeNewswire · 04/26 11:30
Leiv Lea Is The Chief Financial Officer of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) And They Just Picked Up 25% More Shares
Even if it's not a huge purchase, we think it was good to see that Leiv Lea, the Chief Financial Officer of Corvus...
Simply Wall St. · 03/19 12:06
BRIEF-Corvus Pharmaceuticals Provides Business Update And Reports Fourth Quarter And Full Year 2021 Financial Results
reuters.com · 03/10 23:37
More
No Data
Learn about the latest financial forecast of CRVS. Analyze the recent business situations of Corvus Pharmaceu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
50.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CRVS stock price target is 6.38 with a high estimate of 8.00 and a low estimate of 3.500.
High8.00
Average6.38
Low3.500
Current 1.045
EPS
Actual
Estimate
-0.26-0.19-0.13-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 81
Institutional Holdings: 30.83M
% Owned: 66.22%
Shares Outstanding: 46.55M
TypeInstitutionsShares
Increased
14
1.93M
New
7
143.60K
Decreased
17
1.42M
Sold Out
12
940.32K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/President/Chief Executive Officer/Director
Richard Miller
Chief Financial Officer/IR Contact Officer
Leiv Lea
Senior Vice President
William Jones
Senior Vice President
Mehrdad Mobasher
Independent Director
Ian Clark
Independent Director
Elisha Gould
Independent Director
Linda Grais
Independent Director
Edith Mitchell
Independent Director
Scott Morrison
Independent Director
Peter Thompson
No Data
No Data
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist.

Webull offers kinds of Corvus Pharmaceuticals Inc stock information, including NASDAQ:CRVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRVS stock methods without spending real money on the virtual paper trading platform.